Matteo Ferrando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matteo Ferrando has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Giorgio Walter Canonica
Personalized Medicine, Asthma and Allergy Humanitas Clinical & Research Center, IRCCS Rozzano Italy
17 shared publications - Diego Bagnasco
Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy
13 shared publications - Gilda Varricchi
University of Naples Federico II
10 shared publications Giovanni Passalacqua
Allergy & Respiratory Diseases, DIMI Dept of Internal Medicine, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy
9 shared publications- Francesca Puggioni
Humanitas University Department of Biomedical Sciences Milan
6 shared publications Alice Bragantini
Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy
2 shared publications
Latest Publications
- Open Access
- 6 March 2018
- Published by Springer Nature in Clinical and Molecular Allergy
- Vol. 16 (1) , 1-11
A critical appraisal on AIT in childhood asthma
Allergen immunotherapy (AIT) is the only disease-modifying treatment approved for allergic rhinitis and allergic asthma and represents a suitable therapeutic option, especially in childhood, to modify the progression of respiratory allergic diseases. Starting from the previous “generic class effect” evaluation, as testified by the numerous meta analyses, AIT is now considered a product-specific pathogenic-oriented treatment. AIT was empirically proposed more than one century ago in the subcutaneous form (SCIT), but the IgE-mediated mechanism of allergy was elucidated only after 50 years of clinical use of the treatment. The sublingual administration (SLIT) was developed during the 1980 ties, to achieve an improvement in safety and convenience. While SCIT is approved in the United States for the treatment of asthmatic patients with more than 12 years, so far few trials evaluated the clinical efficacy and safety of SLIT in children with allergic asthma, although the indications and some aspects remain unclear. Certainly, due to compliance problems, the age below 3 years may be reasonably considered a practical contraindication. Given that some specific AIT products are effective and approved as drugs (AIFA, EMA, FDA), the use in children is still debated. Some aspects still need robust confirm: (a) the safety of AIT in asthma; (b) the optimal regimen of administration; (c) the role of AIT as preventative treatment for asthma development.
- 6 March 2018
- Published by Springer Nature in Clinical and Molecular Allergy
- Vol. 16 (1) , 1-11
Open AccessA critical appraisal on AIT in childhood asthma
Allergen immunotherapy (AIT) is the only disease-modifying treatment approved for allergic rhinitis and allergic asthma and represents a suitable therapeutic option, especially in childhood, to modify the progression of respiratory allergic diseases. Starting from the previous “generic class effect” evaluation, as testified by the numerous meta analyses, AIT is now considered a product-specific pathogenic-oriented treatment. AIT was empirically proposed more than one century ago in the subcutaneous form (SCIT), but the IgE-mediated mechanism of allergy was elucidated only after 50 years of clinical use of the treatment. The sublingual administration (SLIT) was developed during the 1980 ties, to achieve an improvement in safety and convenience. While SCIT is approved in the United States for the treatment of asthmatic patients with more than 12 years, so far few trials evaluated the clinical efficacy and safety of SLIT in children with allergic asthma, although the indications and some aspects remain unclear. Certainly, due to compliance problems, the age below 3 years may be reasonably considered a practical contraindication. Given that some specific AIT products are effective and approved as drugs (AIFA, EMA, FDA), the use in children is still debated. Some aspects still need robust confirm: (a) the safety of AIT in asthma; (b) the optimal regimen of administration; (c) the role of AIT as preventative treatment for asthma development.
- 1 February 2018
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 18 (1) , 51-58
Asthma: personalized and precision medicine
Purpose of review: In this review, we herein describe the progress in management of severe asthma, evolving from a ‘blockbuster approach’ to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings: Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of ‘personalized medicine’ and ‘precision medicine’, which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics, …) has brought this initially theoretic evolution into a more concrete level. Summary: This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.
- 1 February 2018
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 18 (1) , 51-58
Asthma: personalized and precision medicine
Purpose of review: In this review, we herein describe the progress in management of severe asthma, evolving from a ‘blockbuster approach’ to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings: Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of ‘personalized medicine’ and ‘precision medicine’, which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics, …) has brought this initially theoretic evolution into a more concrete level. Summary: This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.
- Open Access
- 31 August 2017
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 4, 135
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
The definition of asthma has profoundly changed in recent years, thus recognizing that asthma itself is not a single disease but a heterogeneous disorder that includes different phenotypes and, possibly, endotypes. A more detailed knowledge of the immunological mechanisms of the asthma pathogenesis has enabled identifying interleukin 5 (IL-5) as a crucial cytokine in several asthma phenotypes. IL-5, in fact, exerts selective action on eosinophils which, in turn, sustain airway inflammation and worsen asthma symptoms and control. The development of drugs targeting IL-5 or its receptor alpha subunit (IL-5Rα) has been shown, in clinical trials, a promising different therapeutic approach to a problematic type of asthma, the severe one, whose characteristics make the patient not controlled by normal therapies and , until today, only partially controlled by means of systemic steroid therapy with its well-known side-effects or by Omalizumab in the allergic subtypes. Beginning with the design process of clinical trials, the importance of patient selection was immediately identified, taking into account both medical records, such as exacerbations, lung function and quality of life, and biomarkers like eosinophils that were predictive of therapeutic responses
- 31 August 2017
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 4, 135
Open AccessAnti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
The definition of asthma has profoundly changed in recent years, thus recognizing that asthma itself is not a single disease but a heterogeneous disorder that includes different phenotypes and, possibly, endotypes. A more detailed knowledge of the immunological mechanisms of the asthma pathogenesis has enabled identifying interleukin 5 (IL-5) as a crucial cytokine in several asthma phenotypes. IL-5, in fact, exerts selective action on eosinophils which, in turn, sustain airway inflammation and worsen asthma symptoms and control. The development of drugs targeting IL-5 or its receptor alpha subunit (IL-5Rα) has been shown, in clinical trials, a promising different therapeutic approach to a problematic type of asthma, the severe one, whose characteristics make the patient not controlled by normal therapies and , until today, only partially controlled by means of systemic steroid therapy with its well-known side-effects or by Omalizumab in the allergic subtypes. Beginning with the design process of clinical trials, the importance of patient selection was immediately identified, taking into account both medical records, such as exacerbations, lung function and quality of life, and biomarkers like eosinophils that were predictive of therapeutic responses
- 7 July 2017
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 18 (5) , 378-383
New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases
Background: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). Objective: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. Method: In the recent years, several randomized placebo-controlled clinical trials have been performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. Results: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. Conclusion: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma.
- 7 July 2017
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 18 (5) , 378-383
New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases
Background: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). Objective: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. Method: In the recent years, several randomized placebo-controlled clinical trials have been performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. Results: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. Conclusion: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma.
- 21 April 2017
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 26 (6) , 761-766
Umeclidinium for the treatment of uncontrolled asthma
Introduction: Smooth muscle cell contraction in the airways is the principal therapeutic target in asthmatic subjects and its insufficient treatment is often a cause of uncontrolled disease. For this reason, research has focused on targeting smooth muscle activity with anticholinergic agents, including umeclidinium. Areas covered: This review highlights the potential application of umeclidinium, a long acting muscarinic antagonist, as a novel therapeutic approach for patients with severe uncontrolled asthma, despite maximal therapy. Expert opinion: Umeclidinium, similarly to tiotropium, which has been recently included in guidelines, may act by contrasting cholinergic activation in airways, preventing or at least reducing smooth muscle cells contraction and the consequent bronchoconstriction. This is similar to what occurs in chronic obstructive pulmonary disease, for which umeclidinium has been regularly approved. However, available data is not sufficient and further studies are needed before regulatory approval can be sought, since only phase II clinical trials have been conducted at present. Both quality of life and objectifiable clinical data and parameters must be assessed, including lung function improvements, reduction of exacerbations and reduction of as required medications.
- 21 April 2017
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 26 (6) , 761-766
Umeclidinium for the treatment of uncontrolled asthma
Introduction: Smooth muscle cell contraction in the airways is the principal therapeutic target in asthmatic subjects and its insufficient treatment is often a cause of uncontrolled disease. For this reason, research has focused on targeting smooth muscle activity with anticholinergic agents, including umeclidinium. Areas covered: This review highlights the potential application of umeclidinium, a long acting muscarinic antagonist, as a novel therapeutic approach for patients with severe uncontrolled asthma, despite maximal therapy. Expert opinion: Umeclidinium, similarly to tiotropium, which has been recently included in guidelines, may act by contrasting cholinergic activation in airways, preventing or at least reducing smooth muscle cells contraction and the consequent bronchoconstriction. This is similar to what occurs in chronic obstructive pulmonary disease, for which umeclidinium has been regularly approved. However, available data is not sufficient and further studies are needed before regulatory approval can be sought, since only phase II clinical trials have been conducted at present. Both quality of life and objectifiable clinical data and parameters must be assessed, including lung function improvements, reduction of exacerbations and reduction of as required medications.
- 20 March 2017
- Published by Springer Nature in Drug Safety
- Vol. 40 (7) , 559-570
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.
- 20 March 2017
- Published by Springer Nature in Drug Safety
- Vol. 40 (7) , 559-570
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.
- Open Access
- 10 March 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 242
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe uncontrolled disease. Although the majority of patients can be efficiently treated, severe asthmatics continue to be uncontrolled and are at risk of exacerbations and even death. Interleukin-5 (IL-5) plays a fundamental role in eosinophil differentiation, maturation, activation and inhibition of apoptosis. Therefore, targeting IL-5 is an appealing approach to the treatment of patients with severe eosinophilic asthma. Reslizumab, a humanized anti-IL-5 monoclonal antibody, binds with high affinity to amino acids 89 - 92 of IL-5 that are critical for binding to IL-5 receptor Alpha (IL-5Ralpha). Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (Greater than 400 cells/microliter) improved lung function, asthma control and symptoms. Thus, the use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab. In conclusion, targeted therapy with reslizumab represents one step closer to precision medicine in patients with severe eosinophilic asthma.
- 10 March 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 242
Open AccessReslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe uncontrolled disease. Although the majority of patients can be efficiently treated, severe asthmatics continue to be uncontrolled and are at risk of exacerbations and even death. Interleukin-5 (IL-5) plays a fundamental role in eosinophil differentiation, maturation, activation and inhibition of apoptosis. Therefore, targeting IL-5 is an appealing approach to the treatment of patients with severe eosinophilic asthma. Reslizumab, a humanized anti-IL-5 monoclonal antibody, binds with high affinity to amino acids 89 - 92 of IL-5 that are critical for binding to IL-5 receptor Alpha (IL-5Ralpha). Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (Greater than 400 cells/microliter) improved lung function, asthma control and symptoms. Thus, the use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab. In conclusion, targeted therapy with reslizumab represents one step closer to precision medicine in patients with severe eosinophilic asthma.
- Open Access
- 1 January 2017
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 9 (1) , 15-24
Personalized Medicine in Allergy
Ferrando M, et al. Allergy Asthma Immunol Res. 2017 Jan;9(1):15-24. https://doi.org/10.4168/aair.2017.9.1.15
- 1 January 2017
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 9 (1) , 15-24
Open AccessPersonalized Medicine in Allergy
Ferrando M, et al. Allergy Asthma Immunol Res. 2017 Jan;9(1):15-24. https://doi.org/10.4168/aair.2017.9.1.15
- Open Access
- 17 November 2016
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 11 (1) , 40-45
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.
- 17 November 2016
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 11 (1) , 40-45
Open AccessMepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.
- 19 September 2016
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 16 (11) , 1435-1441
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis
Introduction: Since its introduction in clinical practice one century ago for the treatment of respiratory allergic diseases, allergen-specific immunotherapy (AIT) has exhibited a relevant clinical efficacy that was subsequently confirmed in controlled trials. Thus, AIT has been accepted worldwide, as testified by guidelines and international documents. AIT is considered pivotal in the management of allergic rhinitis with or without conjunctivitis and with or without asthma. These conditions, in addition to hymenoptera venom allergy, currently are the accepted indications. The use of AIT in house-dust mite allergy still remains debated, especially due to the methodological problems in assessing this form of respiratory allergy. The more recent experimental data on MK-8237 sublingual tablets provided evidence that AIT, in the sublingual form, is effective in dust mite allergy. Areas covered: At present, the evidence of the efficacy of AIT in conditions other than respiratory allergy are not conclusive, but encouraging results have been obtained in food allergy and atopic dermatitis. Herein, the authors discuss the data for these indications. Expert opinion: Not all patients respond to AIT in the same way. Accordingly, AIT represents a promising path to precision medicine and hopefully will be able to reduce this burden of non-responding patients.
- 19 September 2016
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 16 (11) , 1435-1441
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis
Introduction: Since its introduction in clinical practice one century ago for the treatment of respiratory allergic diseases, allergen-specific immunotherapy (AIT) has exhibited a relevant clinical efficacy that was subsequently confirmed in controlled trials. Thus, AIT has been accepted worldwide, as testified by guidelines and international documents. AIT is considered pivotal in the management of allergic rhinitis with or without conjunctivitis and with or without asthma. These conditions, in addition to hymenoptera venom allergy, currently are the accepted indications. The use of AIT in house-dust mite allergy still remains debated, especially due to the methodological problems in assessing this form of respiratory allergy. The more recent experimental data on MK-8237 sublingual tablets provided evidence that AIT, in the sublingual form, is effective in dust mite allergy. Areas covered: At present, the evidence of the efficacy of AIT in conditions other than respiratory allergy are not conclusive, but encouraging results have been obtained in food allergy and atopic dermatitis. Herein, the authors discuss the data for these indications. Expert opinion: Not all patients respond to AIT in the same way. Accordingly, AIT represents a promising path to precision medicine and hopefully will be able to reduce this burden of non-responding patients.